Reported 2 days ago
Morgan Stanley analyst Judah Frommer has raised the price target for Apellis Pharmaceuticals (APLS) from $25 to $26 while maintaining a Hold rating. This decision is influenced by the company's strong market position and a recent major royalty purchase agreement with Sobi valued at up to $300 million, contributing immediate financial benefits. However, Frommer remains cautious about APLS's future due to regulatory uncertainties tied to upcoming FDA decisions and new product launches.
Source: YAHOO